Small-cell breast carcinoma with response to atezolizumab: a case report.
Immunotherapy
; 2022 Apr 28.
Article
en En
| MEDLINE
| ID: mdl-35481350
Immunotherapy is an emerging area in cancer research which utilizes the body's immune system to target cancerous cells. This offers oncologists an effective alternative to standard chemotherapy options, which often have significant side effects. Additionally, biomarkers including PD-L1 positivity to predict response to immunotherapy are currently under investigation. The patient presented with a rare type of aggressive breast cancer that previously had few treatment options. This report demonstrates the use of biomarker assessment (PD-L1) to predict immunotherapy response. The patient responded well to immunotherapy, and radiologic scans demonstrated tumor reduction. Further research into this field has the implication to improve treatments, decrease side effects of chemotherapy and improve patient outcomes for many cancers.
Texto completo:
1
Base de datos:
MEDLINE
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Immunotherapy
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Año:
2022
Tipo del documento:
Article